Publications by authors named "Anastasia Sioni"
Background: Despite advances in the treatment of oncology patients, therapy-related side effects may lead to premature morbidity. Inflammatory activation that has been linked to cardiovascular disease is crucial for the pathogenesis of both Hodgkin (HL) and non-Hodgkin lymphoma (NHL).
Objectives: The purpose of this study was to assess the vascular effects of chemotherapy in patients with HL and NHL by positron emission tomography/computed tomography with 18-fluorodeoxyglucose (18-FDG PET/CT) and to investigate interactions with systemic inflammation as assessed by circulating inflammatory markers.
Article Synopsis
- Researchers studied how effective new treatments called VRd and DBQ are for patients with a type of blood cancer called primary plasma cell leukemia (pPCL) compared to older treatments.
- They looked at 110 patients and found that those treated with the new treatments had better results, with nearly 83% of them responding well to the treatment.
- Overall, patients using VRd/DBQ lived longer and had fewer complications than those on older treatments, making it the best option for treating pPCL right now.
Article Synopsis
- The study investigated the relationship between lymphoma severity and cardiovascular health, specifically looking at arterial inflammation through FDG uptake in patients with active Hodgkin's and non-Hodgkin's lymphoma.
- Sixty-two chemotherapy-naïve patients were compared to previously treated lymphoma patients to assess metabolic tumor volume and glycolysis associated with arterial fluoride uptake.
- Results showed significant correlations between disease severity and arterial inflammation, with higher FDG uptake in active lymphoma patients compared to controls, particularly in advanced stages of the disease.
Transplant-ineligible relapsed/refractory (rr) diffuse large B-cell lymphoma (DLBCL) patients represent an unmet medical need. Polatuzumab vedotin (Pola), an anti-CD79b antibody-drug-conjugate (ADG), with bendamustine- rituximab(BR) has recently gained approval for these patients, both in the USA and Europe, based on the GO29365 phase IIb trial. Real-life data with Pola are extremely limited.
View Article and Find Full Text PDFBackground: Multiple myeloma (MM) patients presenting with anaemia as their sole clinical manifestation are rare and not fully defined.
Methods: Retrospective multi-site study comparing the characteristics and outcome of MM patients with anaemia only with matched patients, presenting with multi-organ disease.
Results: Anaemia-only patients had a higher percentage of bone marrow monoclonal plasma cells group (median 60% [IQR 42-80%] vs.
Aims: Studies have shown that bortezomib retreatment is effective in relapsed/refractory multiple myeloma (MM). The observational, prospective electronic VELCADE OBservational Study (eVOBS) study assessed bortezomib-based therapies for patients with MM in everyday practice. Here, we report on those patients receiving retreatment with bortezomib.
View Article and Find Full Text PDFCompeting risk survival analysis in patients with symptomatic Waldenström macroglobulinemia: the impact of disease unrelated mortality and of rituximab-based primary therapy.
Haematologica
November 2015
The treatment of Waldenström's macroglobulinemia (WM) has changed over the last decades, mainly because of the introduction of nucleoside analogues and of rituximab while novel agents such as bortezomib have been recently introduced. We performed an analysis to investigate whether the outcome of patients with WM has improved over the last years, compared to that of patients who started treatment before new drugs became widely available, especially as part of the frontline treatment. We analyzed 345 symptomatic patients with WM: 130 who initiated treatment before and 215 who started treatment after January 1, 2000.
View Article and Find Full Text PDFPrognostication of the high-risk WM patient.
Clin Lymphoma Myeloma Leuk
February 2011
Waldenström's macroglobulinemia is characterized by a protracted course in most patients and the median survival may be long. However, a subset of patients may present with more aggressive disease that is associated with short survival. In order to better characterize these "poor-risk" patients, we identified patients who died within 2 years from the initiation of front-line treatment.
View Article and Find Full Text PDFIron overload is present in several cases of double heterozygous sickle-cell/beta-thalassemia (HbS/β-thal). Deferasirox is an orally administered iron chelator which is effective on iron overloaded patients with transfusion-dependent anemia. The aim of this study was to investigate the efficacy and safety of deferasirox on HbS/β-thal patients with iron overload.
View Article and Find Full Text PDFValidation of the International Prognostic Scoring System (IPSS) for Waldenstrom's macroglobulinemia (WM) and the importance of serum lactate dehydrogenase (LDH).
Leuk Res
October 2010
Article Synopsis
- The ISSWM staging system for symptomatic patients with WM was initially based on patients treated with specific therapies and lacks external validation for cause-specific survival.
- An independent validation of ISSWM demonstrated its effectiveness in distinguishing three groups with significantly different overall survival (OS) and cause-specific survival (CSS) among 335 patients treated with primarily alkylating agents and rituximab-based therapies.
- Elevated serum LDH levels were shown to predict shorter OS and CSS, highlighting the need for innovative treatment strategies for patients classified as high risk based on ISSWM and elevated LDH.